•  
  •  
  •  
  •  

2025-11-30 03:13:04

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura

Keywords Selected:  ANDA

Research

  • India Inc revenue growth likely moderated to 4-6% in March quarter - CRISIL Market Intelligence and Analytics

Stock Report

  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • B and A Ltd consolidated Q2FY26 net profit at Rs. 25.49 crores
  • Caplin Steriles Ltd receives USFDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection
  • FDC Ltd receives USFDA approval for ANDA Pilocarpine Hydrochloride Ophthalmic Solutions
  • Caplin Steriles Ltd granted final approval for ANDA Milrinone Lactate in 5% Dextrose Injection by USFDA
  • Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
  • Gland Pharma receives approval for Vasopressin in 5% Dextrose RTU Injection
  • Lupin receives approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • J.B. Chemicals & Pharmaceuticals Ltd receives USFDA approval for ANDA Amitriptyline Hydrochloride Tablets
  • Lupin launches Prucalopride tablets in the United States
  • Lupin receives approval from U.S. FDA for Prucalopride Tablets
  • J B Chemicals and Pharmaceuticals Ltd receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Gland Pharma Receives Approval for Angiotensin II Acetate Injection
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP
  • Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Haloperidol Decanoate Injection
  • Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25, 50, 100 and 200 mg tablets
  • Caplin Steriles Ltd gets USFDA approval for Phytonadione Injectable Emulsion
  • J.B. Chemicals & Pharmaceuticals Ltd receives ANDA approval from USFDA for Bisoprolol Tablets USP
  • Alembic Pharmaceuticals receives USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
  • Bliss GVS Pharma Ltd's partner gets final approval from USFDA for Mesalamine Suppositories 1000 mg

Latest Post

  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024